Target Reached

Telix Pharmaceuticals Limited

August 16, 2020 - 11 months ago
Share on twitter
Share on facebook
Share on linkedin
Share on email
Action Buy
Term 60 Days
Called At $1.355
Target $1.65
Current Price N/A
Performance 21.77%

Technical outlook – Approaching this share from a technical perspective, the current market pattern is nesting on a support base at $1.20 -$1.30.

After assessing the extent of the sell-off at the beginning of July 2020, we believe the bullish pathway is expected to unfold towards the recent highs of $1.60-70


Company Overview – Telix Pharmaceuticals Limited (TLX) is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation.

TLX is headquartered in Melbourne with international operations in Brussels, Kyoto and Indianapolis.

TLX is developing a portfolio of clinical-stage oncology products that address a significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.

Share on twitter
Share on facebook
Share on linkedin
Share on email

Leave a Reply